Background {#Sec1}
==========

Hepatocellular carcinoma (HCC) belongs to the most common human cancer entities and shows an increasing incidence \[[@CR1], [@CR2]\]. With an estimated 5-year-survival rate of 15 % the prognosis of HCC patients is poor \[[@CR3]\]. Curative treatment options are only available for early tumor stages. In particular, patients with a multifocal tumor growth are facing a poor prognosis. Classical chemotherapeutic approaches are largely inefficient due to a pronounced chemoresistance \[[@CR4]\]. To date, the oral multikinase inhibitor sorafenib is the standard systemic treatment for patients with advanced HCC \[[@CR2]\]. The SHARP trial showed an increase in the median overall survival of about 3 months in the sorafenib treatment group \[[@CR5]\]. The effects of sorafenib were slightly weaker in a phase III trial in an asia-pacific population with a more advanced disease \[[@CR6]\]. Unfortunately, a substantial fraction of patients faces serious drug-related adverse events under sorafenib treatment that can even result in drug discontinuation. Diarrhea and hand-foot skin reaction are the most common reactions and occur in about 8--16 % \[[@CR5], [@CR6]\]. Moreover, there are controversial assumptions regarding the cost effectiveness of sorafenib treatment \[[@CR7], [@CR8]\]. These findings underscore the urgent need for biomarkers predicting prognosis and response under treatment with sorafenib. However, convincing biomarkers for the identification of patients that will most likely have a benefit from a systemic treatment with sorafenib are still not defined \[[@CR9]\].

The organic cation transporter OCT1 (gene symbol *SLC22A1*) belongs to the amphiphilic solute facilitator (ASF) family of integral transmembrane proteins \[[@CR10]\]. It is located at the basolateral membrane of hepatocytes \[[@CR11]\]. The physiologic role of OCT1 is the uptake of a broad range of endogenous (e. g. catecholamines and prostaglandins) and exogenous substrates including anticancer drugs like tyrosine kinase inhibitors (e. g. sorafenib) \[[@CR11]--[@CR13]\]. We could show previously that intratumoral downregulation of OCT1 correlates with a worse survival in HCC \[[@CR10]\]. In addition, a high pretherapeutic OCT1 expression predicts a complete molecular response to the tyrosine kinase inhibitor imatinib in chronic myeloid leukemia (CML) \[[@CR14]\]. It is known that a reduced or aberrant OCT1 expression prevents a sufficient intracellular sorafenib concentration \[[@CR13]\].

It was the aim of this retrospective study to define whether OCT1 mRNA expression is a useful biomarker in the systemic therapy of HCC with sorafenib.

Methods {#Sec2}
=======

Patient characteristics and tissue samples {#Sec3}
------------------------------------------

Clinical data and tumor samples of 60 patients that underwent liver biopsy at the University Medical Center Mainz between January 2001 and December 2013 were analyzed in this study. Clinical and pathological characteristics of this cohort are summarized in Table [1](#Tab1){ref-type="table"}. Primary inclusion criteria were liver biopsy, treatment with sorafenib and registration in the HCC database Mainz. Main exclusion criteria were insufficient RNA-extraction from liver tissue and curative liver transplantation without post-transplant tumor recurrence. All HCC were histologically confirmed. This study was approved by the ethics committee of the local medical board Rhineland-Palatinate and was conducted according to the ethical guidelines of the Declaration of Helsinki. Written informed consent was given by each patient. The liver tissues analyzed in this study were embedded in paraffin. For the evaluation of an AFP response, only patients with AFP levels \> 20 ng/ml (AFP-positive HCC) were included. Due to the retrospective approach, AFP response was determined individually at variable time points after initiation of sorafenib treatment.Table 1Patients and tumor characteristicsCharacteristics n60Gender male54 female6Mean age years (standard deviation)64.8 (10.7)Underlying disease alcohol16 HBV11 HCV12 steatosis or NASH5 others11 unknown5Prior HCC treatment yes35 no25Tumor grading G113 G234 G38 unknown5Tumor burden MVIabsent31present29 EHSabsent17present43 MVI and/or EHSabsent6present54BCLC classification A1 B1 C50 D6 unknown2ECOG PS 011 139 25 32 unknown3Child-Pugh A14 B24 C4 unknown18Ascites absent23 present19 unknown18Baseline AFP (ng/ml) ≤2022 \>2036 unknown2

RNA isolation, RT-PCR and real-time RT-PCR analysis {#Sec4}
---------------------------------------------------

Paraffin embedded tissue sections of 5-10 μm thickness were used for RNA isolation. Hemo-De solvent (Scientific Safety Solvents, Keller, USA) and the High Pure RNA Paraffin Kit (Roche, Mannheim, Germany) were used for deparaffinization according to the manufacturer's recommendations. The iScript cDNA Synthesis kit (Biorad, Munich, Germany) was applied for cDNA synthesis from total RNA according to the manufacturer's recommendations. Quantification of OCT1 (*SLC22A1*) transcripts was performed by real-time PCR. Quantitect SYBR Green PCR Kit (QIAGEN, Hilden, Germany) and validated primers of a Quantitect Primer Assay with the primer sets Hs_SLC22A1_1\_SG (QT00019572) and Hs_GAPDH_2\_SG (QT01192646) were used according to the manufacturer's recommendations (QIAGEN, Hilden, Germany). Primer sequences are considered commercially sensitive by the manufacturer and cannot be published. For the amplification, an initial denaturation (15 min at 95 °C) followed by 50 cycles of denaturation (15 s at 94 °C), annealing (30 s at 55 °C), and elongation (30 s at 72 °C). A LightCycler® 480 real-time PCR system (Roche, Mannheim, Germany) was used. Relative expression level of OCT1 (SLC22A1) was calculated by normalization to GAPDH gene expression using LightCycler® 480 software version 1.5.0.

Statistical analysis {#Sec5}
--------------------

Statistical analyses were performed using SPSS (IBM® SPSS® 21 version 21.0.0.1). For descriptive analyses, mean and standard deviation were calculated for continuous variables. In addition, absolute and relative frequencies were computed for categorical variables. Quantitative, normally distributed variables were analyzed using the unpaired t-test. For the analysis of categorical variables, we used Fisher's exact test or Mann--Whitney U test. Survival rates between both OCT1 groups were compared by the log-rank test. For graphical visualization Kaplan-Meier curves are presented. The univariable test results have to be considered as explorative. No adjustments for multiple testing have been done here. *P*-values are given for descriptive reasons only. A multivariable Cox regression model adjusted for age was performed for confirmatory analysis with a significance level of 5 %. Hazard ratios with their corresponding *p*-values and 95 % confidence limits are presented.

Results {#Sec6}
=======

Expression of OCT1 (SLC22A1) mRNA in HCC biopsies {#Sec7}
-------------------------------------------------

First, we analyzed the intratumoral OCT1 mRNA expression levels. The relative OCT1 expression levels in HCC tissue ranged between 0.0037 and 9.711 with a lower quartile of 0.227.

Survival according to intratumoral OCT1 mRNA expression {#Sec8}
-------------------------------------------------------

Cox regression analysis revealed a significant positive association between OCT1 mRNA expression level and patient survival in patients treated with sorafenib (HR 0.653; 95 %-CI 0.430-0.992; *p* = 0.046; Table [2](#Tab2){ref-type="table"}). Patient age at beginning of sorafenib treatment did not have a significant impact (*p* = 0.144). As the majority of patients in this cohort were male, the variable gender was excluded in the cox regression analysis. A sensitivity analysis showed a slight but relevant survival benefit in the univariable log-rank test using the lower quartile of OCT1 mRNA expression as a cutoff (*p* = 0.049; Fig. [1](#Fig1){ref-type="fig"}). According to the sensitivity analysis, patients were subdivided into two groups by the intratumoral OCT1 mRNA expression level (\<lower quartile vs. ≥ lower quartile, Fig. [2](#Fig2){ref-type="fig"}).Table 2Cox regressionHR95 %-CI*P*-valueOCT1 expression level \[log10\]0.6530.430 -- 0.9920.046age (begin sorafenib) \[years\]0.9800.955 -- 1.0070.144Fig. 1Survival according to the intratumoral OCT1 expression. Patient groups were compared by lower quartile of intratumoral OCT1 expression according to a sensitivity analysisFig. 2Intratumoral OCT1 expression according to median. The patients were sorted by intratumoral OCT1 expression (*n* = 60). Two patient groups were defined according to the lower quartile of intratumoral OCT1 expression

OCT1 mRNA expression in correlation with patient and tumor characteristics {#Sec9}
--------------------------------------------------------------------------

Patients and tumor characteristics are listed in Table [1](#Tab1){ref-type="table"}. No differences between the two groups (OCT1 mRNA expression \< lower quartile vs. ≥lower quartile) could be shown regarding formerly described relevant baseline characteristics like presence of ascites (*p* = 0.504), Barcelona-Liver Cancer Clinic stage (BCLC stage, *p* = 0.988), and Eastern Cooperative Oncology Group Performance status (ECOG; *p* = 0.099, Table [3](#Tab3){ref-type="table"}). Macrovascular invasion (MVI) was slightly more frequent in the group showing a low OCT1 mRNA expression (*p* = 0.037, Table [3](#Tab3){ref-type="table"}). Prior HCC treatment did not have a statistically significant impact.Table 3Patients and tumor characteristics according to the intratumoral OCT1 mRNA expressionCharacteristicsOCT1 (*SLC22A1*)OCT1 (*SLC22A1*)*P*-valueLow expressionHigh expression(\< lower quartile)(≥ lower quartile)*n*1545Gender male1440 female151.000\
(Fisher's exact test)Mean age years (standard deviation)65.022 (7.190)64.658 (11.667)0.910\
(unpaired t test)Underlying liver disease alcohol214 HBV38 HCV48 steatosis or NASH05 others56 unknown140.224\
(Fisher's exact test)Prior HCC treatment yes629 no9160.133\
(Fisher's exact test)Tumor grading G1310 G2826 G344 unknown050.265\
(Mann--Whitney U test)Tumor burdenMVI          absent427          present11180.037\
(Fisher's exact test)EHS         absent512          present10330.743\
(Fisher's exact test)MVIand/or EHS      absent15          present14401.000\
(Fisher's exact test)BCLC classification A01 B10 C1238 D24 unknown020.988\
(Mann--Whitney U test)ECOG PS 029 1831 223 320 unknown120.099\
(Mann--Whitney U test)Child-Pugh A113 B1113 C04 unkown3150.195\
(Mann--Whitney U test)Ascites absent518 present613 unknown4140.504\
(Fisher's exact test)Baseline AFP (ng/ml) ≤20220 \>201125 unknown200.103\
(Fisher's exact test)mean durationsorafenib treatment days (standard deviation)161 (126)149 (128)0.764\
(unpaired t test)

AFP response according to the intratumoral OCT1 mRNA expression {#Sec10}
---------------------------------------------------------------

For the evaluation of the AFP response, only patients with AFP levels \>20 ng/ml (AFP-positive HCC) were included in the analysis. Patients were only categorized as AFP responders if a reduction in AFP levels of at least 20 % was achieved under treatment with sorafenib \[[@CR15], [@CR16]\]. Table [4](#Tab4){ref-type="table"} shows the AFP response of the AFP positive patients in this cohort according to the OCT1 mRNA expression (\<lower quartile vs. ≥lower quartile; *n* = 36). Concerning the AFP response under treatment with sorafenib, there were no differences between the OCT1 mRNA low and the OCT1 mRNA high expression groups in this cohort (*p* = 0.633, Table [4](#Tab4){ref-type="table"}).Table 4AFP responseBaseline AFP (ng/ml) \>20OCT1 (*SLC22A1*)OCT1 (*SLC22A1*)*P*-valueLow expressionHigh expression(\< lower quartile)(≥ lower quartile)n1125AFP responders16AFP non-responders714unknown350.633\
(Fisher's exact test)

Discussion {#Sec11}
==========

Intratumoral downregulation of OCT1 in HCC has been described by us and others \[[@CR10], [@CR13]\]. In a previous work we showed that down-regulation of OCT1 is associated with reduced survival in patients that underwent liver resection or transplantation \[[@CR10]\]. Whether reduced intratumoral OCT1 mRNA expression assessed from tumor biopsies is of prognostic value under sorafenib treatment has not been defined yet. We performed this retrospective study as the identification of novel biomarkers in HCC treatment is of special interest in terms of individualized medicine.

For this analysis, OCT1 mRNA was quantified with a commercially available primer set that has been comprehensively validated and correlated with OCT1 protein expression by our group \[[@CR10], [@CR17]\]. OCT1 exhibits SNPs that might affect OCT1 function. In the background of CML, several studies investigated the association between OCT1 SNPs and clinical outcome with contradictory results \[[@CR18]--[@CR21]\]. Importantly, one study suggests that contradictory results might be due to interference between SNPs and primer sites \[[@CR19]\]. Upon request, the manufacturer of the primer assays used in this study ensured that the primer sites do not interfere with the most relevant SNPs as proposed by Giannoudis et al. \[[@CR19]\]. A sensitivity analysis revealed that particularly patients with a baseline OCT1 mRNA expression within the range of the lower quartile have a significantly impaired survival under treatment with sorafenib. The poor prognosis under treatment might be at least in part explained by a reduced OCT1-mediated drug uptake due to non-functional, truncated proteins \[[@CR13]\].

This retrospective analysis shows that a reduced intratumoral OCT1 mRNA expression results in a worse survival in patients treated with sorafenib. This effect is independent of other strong prognostic factors like the presence of ascites, BCLC stage and ECOG performance status \[[@CR22]\]. A correlation between the prognostically unfavorable low intratumoral OCT1 expression and MVI could be shown here if the lower quartile of OCT1 expression was used as a cutoff (*p* = 0.037). This correlation is not significant if the cutoff is median OCT1 expression (*p* = 0.120, data not shown). Also in previous studies using median OCT1 expression as a cutoff, a statistically significant correlation between OCT1 expression and MVI was not shown \[[@CR10]\]. The impact of this observation will be further analyzed in a subsequent study.

The prognostic role of tumor markers like AFP in HCC has been studied extensively \[[@CR23]\]. Previous studies showed that AFP response was significantly associated with the overall survival also in patients with advanced HCC treated with sorafenib \[[@CR16]\]. Probably due to variable times of AFP measurement in this retrospective analysis we could not reproduce this finding in the context of OCT1 mRNA expression levels.

A limitation of the current study is the retrospective nature of data collection. The biopsies were acquired in context of primary diagnosis of the HCC. Variations in tumor genetics may occur during the course of disease \[[@CR24]\]. In addition, the time frame between biopsy acquisition and beginning of sorafenib treatment varies. Due to this fact, a lead time bias and effects on the basis of variable stages of tumor spread should be considered \[[@CR25]\]. Some patients enrolled in this analysis have been treated in the early phase after approval of sorafenib. Initially, few patients with reduced liver function and performance status were treated with sorafenib. To date, guidelines do not recommend the use of sorafenib in these patients \[[@CR2]\]. As common for retrospective trials, the reliability and validity of patient's report in terms of adherence to medication remains unknown \[[@CR26]\]. Radiological response could not be correlated with OCT1 mRNA expression levels in this cohort due to a lack of data.

Although the acquisition of HCC tissue via transcutaneous biopsy is a feasible method with a good risk-benefit ratio, it should be considered that intratumoral heterogeneity in OCT1 mRNA expression might occur. The alternative approach of a HCC resection remains reserved to a relatively small fraction of patients \[[@CR2]\]. However, facing all the drawbacks, the identification of patient subgroups with the best response to an antitumor agent in HCC by information drawn from tumor biopsies is still a promising approach.

Conclusions {#Sec12}
===========

The identification of novel biomarkers for anticancer therapy is of particular importance in terms of prevention of side effects caused by therapeutics with limited efficacy in the individual patient as well as for economic reasons. This study shows that intratumoral OCT1 mRNA expression might play a role as a prognostic biomarker in sorafenib-based HCC therapy. Further, prospective trails are warranted on this topic.
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:   macrovascular invasion
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:   extrahepatic spread
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:   alpha-fetoprotein
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